Pin1与VEGF在肺癌中的表达及相关性
The Expression and Correlation of Pin1 and VEGF in Lung Cancer
DOI: 10.12677/ACM.2023.1361409, PDF,   
作者: 王 珊：华北理工大学研究生学院，临床医学院，河北 唐山 ；郭丽颖：河北医科大学研究生学院，临床医学院，河北 石家庄 ；宋文广：唐山市工人医院，肿瘤内科，河北 唐山
关键词: 肺癌；Pin1；VEGF；综述；Lung Cancer； Pin1； VEGF； Summary
摘要: Pin1是一肽脯氨酰异构酶，能特异性地催化靶蛋白，细胞的正常增殖与分化，以及肿瘤的转移与生长受到蛋白质中的Ser-Pro (丝氨酸–脯氨酸)或Thr-Pro (苏氨酸–脯氨酸)的磷酸化调控。通过抑制pin1活性，从而可达到抑制肿瘤细胞生长的目的。VEGF是一种功能强大且能产生多种生物学效应的细胞因子，在创伤组织及肿瘤组织中，均可产生高表达，而高表达的VEGF更容易产生利于肿瘤生长的微环境。Pin1和VEGF在肺癌中高表达，可被用于肿瘤标志物的检测指标，或作为双靶点联合治疗肺癌的突破口，本文综述了Pin1与VEGF功能与结构，为肺癌的发生发展和治疗方法提供有利的依据，为肺癌患者的多通道联合治疗提供有力的支持。
Abstract: Pin1 is a peptide prolyl isomerase that can specifically catalyze target proteins. Normal cell prolif-eration and differentiation, as well as tumor metastasis and growth, is regulated by the phosphory-lation of Ser Pro (serine proline) or Thr Pro (threonine proline) in proteins. By inhibiting the activi-ty of pin1, the goal of inhibiting tumor cell growth can be achieved. VEGF is a powerful cytokine that can produce a variety of biological effects. It can be highly expressed in both traumatic and tumor tissues, and highly expressed VEGF is more likely to produce a microenvironment conducive to tu-mor growth. Pin1 and VEGF are highly expressed in lung cancer and can be used as detection indi-cators for tumor markers, or as a breakthrough point for dual target combination therapy of lung cancer. This article reviews the function and structure of Pin1 and VEGF, providing favorable basis for the occurrence, development, and treatment methods of lung cancer, and providing strong sup-port for multi-channel combination therapy of lung cancer patients.
文章引用：王珊, 郭丽颖, 宋文广. Pin1与VEGF在肺癌中的表达及相关性[J]. 临床医学进展, 2023, 13(6): 10075-10080. https://doi.org/10.12677/ACM.2023.1361409

参考文献

[1] Torre, L.A., Bray, F., Siegel, R.L., Ferlay, J., Lortet-Tieulent, J. and Jemal, A. (2012) Global Cancer Statistics, 2012. CA: A Cancer Journal for Clinicians, 65, 87-108. [Google Scholar] [CrossRef] [PubMed]
[2] Global Burden of Disease Cancer Collaboration (2019) Global, Regional, and National Cancer Incidence, Mortality, Years of Life Lost, Years Lived with Disability, and Disability-Adjusted Life-Years for 29 Cancer Groups, 1990 to 2017: A Systematic Analysis for the Global Burden of Disease Study. JAMA Oncology, 5, 1749-1768.
[3] Siegel, R.L., Miller, K.D. and Jemal, A. (2020) Cancer Statistics, 2020. CA: A Cancer Journal for Clinicians, 70, 7-30. [Google Scholar] [CrossRef] [PubMed]
[4] Herbst, R.S., Heymach, J.V. and Lippman, S.M. (2008) Lung Cancer. The New England Journal of Medicine, 359, 1367-1380. [Google Scholar] [CrossRef] 
[5] Thakur, C. and Chen, F. (2015) Current Understanding of Mdig/MINA in Human Cancers. Genes and Cancer, 6, 288-302. [Google Scholar] [CrossRef] [PubMed]
[6] Xu, Z.Y., Blot, W.J., Xiao, H.P., et al. (1989) Smoking, Air Pol-lution, and the High Rates of Lung Cancer in Shenyang, China. JNCI: Journal of the National Cancer Institute, 81, 1800-1806. [Google Scholar] [CrossRef] [PubMed]
[7] Cannon-Albright, L.A., Carr, S.R. and Akerley, W. (2019) Population-Based Relative Risks for Lung Cancer Based on Complete Family History of Lung Cancer. Journal of Tho-racic Oncology, 14, 1184-1191. [Google Scholar] [CrossRef] [PubMed]
[8] Zheng, M. (2016) Classification and Pathology of Lung Cancer. Surgical Oncology Clinics of North America, 25, 447-468. [Google Scholar] [CrossRef] [PubMed]
[9] Denisenko, T.V., Budkevich, I.N. and Zhivotovsky, B. (2018) Cell Death-Based Treatment of Lung Adenocarcinoma. Cell Death & Disease, 9, Article 117. [Google Scholar] [CrossRef] [PubMed]
[10] 钟起祥. 2011-2020年间中国医科大学附属第一医院原发性肺癌手术患者临床特征回顾性分析[D]: [硕士学位论文]. 沈阳: 中国医科大学, 2021.[CrossRef] 
[11] Greenawalt, E.J., Edmonds, M.D., Jain, N., Adams, C.M., Mitra, R. and Eischen, C.M. (2019) Targeting of SGK1 by MiR-576-3p Inhibits Lung Adenocarcinoma Migration and Invasion. Molecular Cancer Research, 17, 289-298. [Google Scholar] [CrossRef] 
[12] Hirsch, F.R., Scagliotti, G.V., Mulshine, J.L., Kwon, R., Curran Jr, W.J., Wu, Y.L., et al. (2017) Lung Cancer: Current Therapies and New Targeted Treatments. The Lancet, 389, 299-311. [Google Scholar] [CrossRef] 
[13] Wood, S.L., Pernemalm, M., Crosbie, P.A. and Whetton, A.D. (2014) The Role of the Tumor-Microenvironment in Lung Cancer-Metastasis and Its Relationship to Po-tential Therapeutic Targets. Cancer Treatment Reviews, 40, 558-566. [Google Scholar] [CrossRef] [PubMed]
[14] Wang, L., Zhu, B., Zhang, M.M. and Wang, X.D. (2016) Roles of Immune Microenvironment Heterogeneity in Therapy-Associated Biomarkers in Lung Cancer. Seminars in Cell & De-velopmental Biology, 64, 90-97. [Google Scholar] [CrossRef] [PubMed]
[15] Wintjens, R., Wieruszeski, J.M., Drobecq, H., et al. (2001) 1H NMR Study on the Binding of Pin1 Trp-Trp Domain with Phosphothreonine Peptides. Journal of Biological Chemistry, 276, 25150-25156. [Google Scholar] [CrossRef] 
[16] Blume-Jensen, P. and Hunter, T. (2001) Oncogenic Kinase Signaling. Nature, 411, 355-365. [Google Scholar] [CrossRef] [PubMed]
[17] Lu, K.P., Liou, Y.C. and Zhou, X.Z. (2002) Pinning down the Pro-line-Directed Phosphorylation Signaling. Trends in Cell Biology, 12, 164-172. [Google Scholar] [CrossRef] 
[18] 李红雨, 朱涛, 周金华, 等. 短发夹状RNA干扰对子宫颈癌细胞中Pin1基因表达及细胞增值和凋亡的影响[J]. 中华妇产科杂志, 2006, 41(6): 417-421.
[19] Rippmann, G.F., Hobbie, S., Daibber, C., et al. (2000) Phosphorylation-Dependent Praline Isomerization Catalyzed by Pin1 Is Es-sential for Tumor Cell Survival and Entry into Mitosis. Cell Growth & Differentiation, 11, 409-416.
[20] Motz, G.T., Santoro, S.P., Wang, L.P., et al. (2014) Tumor Endothelium FasL Establishes a Selective Immune Barrier Promoting Tolerance in Tumors. Nature Medicine, 20, 607-615. [Google Scholar] [CrossRef] [PubMed]
[21] Rivera, L.B., Meyronet, D., Hervieu, V., et al. (2015) Intratumoral Myeloid Cells Regulate Responsiveness and Resistance to Antiangiogenic Therapy. Cell Reports, 11, 577-591. [Google Scholar] [CrossRef] [PubMed]
[22] Falcon, B.L., O’Clair, B., Mc Clure, D., et al. (2013) Development and Characterization of a High-Throughput in vitro Cord Formation Model In-sensitive to VEGF Inhibition. Journal of Hematology＆Oncology, 6, Article 31. [Google Scholar] [CrossRef] [PubMed]
[23] Wang, S.H., Cang, S.D. and Liu, D. (2016) Third-Generation Inhibi-tors Targeting EGFR T790M Mutation in Advanced Non-Small Cell Lung Cancer. Journal of Hematology & Oncology, 9, Article No. 34. [Google Scholar] [CrossRef] [PubMed]
[24] Liotta, L.A., Steeg, P.S. and Stetler-Stevenson, W.G. (1991) Can-cer Metastasis and Angiogenesis: An Imbalance of Positive and Negative Regulation. Cell, 64, 327-336. [Google Scholar] [CrossRef] 
[25] Woodhouse, E.C., Chuaqui, R.F. and Liotta, L.A. (1997) General Mechanisms of Metastasis. Cancer, 80, 1529-1537. [Google Scholar] [CrossRef] 
[26] Welsh, S.J., Bellamy, W.T., Briehl, M.M. and Powis, G. (2002) The Redox Protein Thioredoxin-1 (Trx-1) Increases Hypox-ia-Inducible Factor 1 Alpha Protein Expression: Trx-1 Overexpression Results in Increased Vascular Endothelial Growth Factor Production and Enhanced Tumor Angiogenesis. Cancer Research, 62, 5089-5095.
[27] Kim, M.R., Choi, H.S., Heo, T.H., Hwang, S.W. and Kang, K.W. (2008) Induction of Vascular Endothelial Growth Factor by Peptidyl-Prolyl Isomerase Pinl in Breast Cancer Cells. Biochemical and Biophysical Research Communications, 369, 547-553. [Google Scholar] [CrossRef] [PubMed]
[28] Lee, C.C., Chen, S.C., Tsai, S.C., Wang, B.W., Liu, Y.C., Lee, H.M. and Shyu, K.G. (2005) Hyperbaric Oxygen Induces VEGF Expression through ERK, JNK and c-Jun/AP-1 Acti-vation in Human Umbilical Vein Endothelial Cells. Journal of Biomedical Science, 13, 143-156. [Google Scholar] [CrossRef] [PubMed]
[29] Textor, B., Sator-Schmitt, M., Richter, K.H., Angel, P. and Schorpp-Kistner, M. (2006) c-Jun and JunB Are Essential for Hypoglycemia-Mediated VEGF Induction. Annals of the New York Academy of Sciences, 1091, 310-318. [Google Scholar] [CrossRef] [PubMed]
[30] 钱颖. 应用RNAi技术抑制Pin1基因表达对宫颈癌生物学行为的影响及其机制研究[D]: [博士学位论文]. 武汉: 华中科技大学, 2008.
[31] Bao, L., Kimzey, A., Sauter, G., et al. (2004) Prevalent Overexpression of Proly1 Isomerase Pin1 in Human Cancers. The American Journal of Pathology, 164, 1727-1737. [Google Scholar] [CrossRef] 
[32] Ayala, G., Wang, D., Wulf, G., et al. (2003) Pin1 Is a Novel Prognostic Marker in Prostate Cancer. Cancer Research, 63, 6224-6251.
[33] Pang, R.W., Lee, T.K., Man, K., et al. (2006) Pin1 Expression Contributes to Hepatic Carcinogenesis. The Journal of Pathology, 210, 19-25. [Google Scholar] [CrossRef] [PubMed]
[34] Ryo, A., Uemura, H., Ishiguro, H., et al. (2005) Stable Suppression of Tu-morigenicity by Pin1-Targeted RNA Interference in Prostate Cancer. Clinical Cancer Research, 11, 7523-7531. [Google Scholar] [CrossRef] 
[35] Volm, M., Koomagi, R. and Mattern, J. (1999) PD-ECGF, bFGF, and VEGF Expression in Non Small Cell Lung Carcinomas and Their Association with Lymph Node Metastasis. Anticancer Research, 19, 651-655.
[36] 郜娜, 杨庆宇. 基于Notch通路研究南蛇藤提取物对非小细胞肺癌血管生成影响[J]. 热带医学杂志, 2020, 20(3): 341-345.
[37] 周昊旻. mdig调控非小细胞肺癌脉管生成的分子机制研究[D]: [硕士学位论文]. 沈阳: 中国医科大学, 2021.[CrossRef] 
[38] 付文娜, 吴琼, 王慧莉. 凝血酶抑制剂亭扎肝素对肺癌血管生成的抑制作用及分子机制研究[J]. 实用临床医药杂志, 2022, 26(7): 67-72, 77.
[39] 陈璐, 何嘉文, 李姝君. KPT-6566对肺癌细胞增殖、侵袭、凋亡的影响及机制[J]. 山东医药, 2020, 60(31): 19-23.
[40] Sasaki, R. (1996) Microvessel Count and Vascular Endothelial Growth Factor in Renal Cell Carcinoma. The Japanese Journal of Urology, 87, 1032-1040. [Google Scholar] [CrossRef] [PubMed]
[41] Huang, C.Y. and Shen, Z.Y. (2002) Vascular Endothelial Growth Factor—Fundamental Research and Experimental Study in Plastic Surgery. Chinese Journal of Re-parative and Reconstructive Surgery, 16, 64-69.
[42] Baker, E.A., Bergin, F.G. and Leaper, D.J. (2000) Plasminogen Activator System Vascular Endothelial Growth Factor and Colorectal Cancer Progression. Journal of Molecular Pathol-ogy, 53, 307-312. [Google Scholar] [CrossRef] [PubMed]
[43] Ravi, R., Mookergee, B., Bhujwalla, Z., et al. (2000) Regulation of Tumor Angiogensis by p53 Induced Degradation of Hypoxia-Inducible Factor 1a. Genes & Development, 14, 34-44. [Google Scholar] [CrossRef] 
[44] Soumitro, P., Kaustubh, D. and Dababtata, M. (2001) Central Role of p53 on Regulation of Vascular Permeability Factor/Vascular Endothelial Factor (VPF/VEGF) Expression in Mammary Carcinoma. Cancer Research, 61, 6952-6956.

为你推荐